|
For
Immediate Release, March 5, 2002
Damian Lamb, Genesys Capital, Joins Affinium Pharmaceuticals Board of Directors TORONTO,
ONTARIO (March 5, 2002) - Affinium Pharmaceuticals, a leader in structure
guided drug discovery, today announced the appointment of Mr. Damian
Lamb to the Board of Directors.
Along with Kelly Holman, Mr. Lamb is a Founder and Managing Director of Genesys Capital Partners, Inc. of Toronto, Canada. Prior to founding Genesys, Mr. Lamb was Investment Manager with MDS Capital Corp., where his efforts were focused on investments in the area of genomics, drug discovery platform technologies and e-health. Mr. Lamb holds an M.Sc. from McMaster University, where he conducted molecular neurobiology research, and an M.B.A. from Queen's University. Affinium™ Chairman and CEO Dr. John D. Mendlein described Mr. Lamb as a sophisticated life sciences investor who brings to our Board critical thinking and management experience. We are delighted that Damian will join our Board to assist us in the next phase of Affinium's growth. With experience in building, managing and providing financing for high technology and biotechnology companies, Genesys Capital Partners has developed a strong business, professional and scientific network that provides practical insights into biotechnology-based opportunities. Affinium Pharmaceuticals is a structure guided drug discovery company. The Company's proprietary, integrated drug discovery process is designed for rapid advancement of small molecule programs from gene to clinic. The Company's processes enable high throughput target production, determination of target function/structure, and determination of target structure with bound hits and leads to accelerate chemistry for new medicines. The Company also integrates the premier discovery capabilities of Aurora Biosciences to advance Affinium's internal drug discovery efforts. Affinium's processes feature mass spectrometry, NMR (nuclear magnetic resonance) spectroscopy and X-ray crystallography technologies from Bruker Daltonics (Nasdaq: BDAL), Bruker BioSpin and Bruker AXS (Nasdaq: BAXS), respectively. The Company's investors include the Lombard Odier Immunology Fund, Genesys Capital Partners Inc., and HBM BioVentures (Henri B. Meier, Chairman), as well as industrial partners Aurora Biosciences and the Bruker Companies. The Company's Founders, Drs. Aled Edwards, Cheryl Arrowsmith and Jack Greenblatt, are world experts in determination of target function and structure and remain actively involved in the Company. The Company has raised US $33 million since its inception in 2000. AFFINIUM and AFFINIUM PHARMACEUTICALS are trade-mark names of Integrative Proteomics, Inc. For more information, please contact: Affinium™ Pharmaceuticals Contact:
Dr. Joanne E. Harack |